From Wikipedia, the free encyclopedia - View original article
|This article needs more medical references for verification or relies too heavily on primary sources. (May 2013)|
Neuroaid (also NeuroAiD, MLC 601, or MLC 901) is a claimed treatment for stroke sold by Moleac Pte Ltd, a biopharmaceutical company in Singapore. There are two versions: Neuroaid (MLC601) and Neuroaid II (MLC901), with differing blends of ingredients. The ingredients total 14 for both, with nine derived from plants and five from animals.
|List of ingredients in Neuroaid MLC 601 |
|Radix astragali (Milk-vetch or Goats-thorn)|
|Radix salviae miltiorrhizae (red sage or Chinese sage)|
|Radix paeoniae rubra (Chinese peony or common garden peony)|
|Radix angelicae sinensis (dong quai or female ginseng)|
|Prunus persica (peach)|
|Rhizoma acori tatarinowi|
|Buthus martensii (scorpion)*|
|Eupolyphaga Seu Steleophaga (cockroach or tu bie cong)*|
|Calculus Bovis Synthetic/Artifactus (cow bile)*|
|Cornu saigae tataricae (horn of an endangered antelope species)*|
Neuroaid has been shown to stimulate the secretion of brain-derived neurotrophic factor (BDNF). The in vitro and in vivo results show that it makes cells more resistant against glutamate aggression, increases neurite outgrowth and connectivity as well as reduces the infarct volume.
In 2008, a study showed Neuroaid does not modify hemostasis, hematology, and biochemistry in normal subjects and stroke patients. This clinical trial found no interaction of NeuroAid with aspirin. Moreover, the treatment does not increase the risk of bleeding, thrombosis, and has no effect on blood pressure, liver, or kidneys functions.
A study in rodents indicated that MLC 901 had neuroprotective, neuroplasticity and neuroproliferative (neurogenesis) effects.
In 2009, a paper summarized unpublished data on a clinical trial comparing Neuroaid to another traditional Chinese medicine (Buchang Naoxintong Jiaonang) on 605 patients in post stroke recovery. Patients started Neuroaid at least two weeks and less than 6 month after their stroke. The research showed that patients taking Neuroaid had a greater improvement in a measure of functionality at 1 month of treatment, whereas no significant benefit was observed in either group in terms of neurological deficit score and individual scores. Nausea and vomiting were reported as side effects.
A 2013 systematic review noted limitations in the available evidence, but concluded that there was some evidence that Neuroaid (MLC 601) "could be effective in further improving functional independence and motor recovery and is safe for patients with primarily nonacute stable stroke."
A study conducted in Asia on 1100 patients, initiated on Neuroaid within 72 hours of the stroke onset as an add on to medication concluded that MLC601 is statistically no better than placebo in improving outcomes at 3 months when used among patients with acute ischemic stroke of intermediate severity.
The double blind placebo-controlled randomized Phase II Pilot study called TIERS was conducted on 40 patients receiving MLC601 3 times a day for four weeks. The treatment was initiated less than one month after the stroke. The results published in 2009 showed that there were no significant statistical differences between the placebo and the Neuroaid groups.